BAM15 vs CagriSema
A side-by-side research comparison of BAM15 and CagriSema across mechanism, dosing, half-life, benefits, side effects and research status.
Comparison table
| Attribute | BAM15 | CagriSema |
|---|---|---|
| Full name | BAM15 (Mitochondrial Uncoupler) | CagriSema (Cagrilintide + Semaglutide) |
| Category | Weight Management | Weight Management |
| Status | Research compound (preclinical) | Phase 3 Clinical Trial |
| Mechanism | Selectively transports protons across the inner mitochondrial membrane, dissipating the proton gradient as heat rather than ATP. Cells burn more substrate (fat and glucose) to maintain energy, increasing metabolic rate without stimulating the CNS. | Dual-pathway activation: cagrilintide mimics amylin to activate area postrema satiety centers, while semaglutide activates GLP-1 receptors for complementary appetite suppression. |
| Molecular weight | 402.28 Da | Combination product |
| Half-life | Short (hours in animal models) | 7 days (both components) |
| Bioavailability | Oral (animal studies) | High (SubQ) |
| Typical dose | Not established for humans | Cagrilintide 2.4mg + Semaglutide 2.4mg |
| Frequency | Research protocols only | Once weekly |
| Route | Oral (research) | Subcutaneous |
BAM15 reported benefits
- Increases metabolic rate/energy expenditure
- Fat loss without appetite suppression
- Improved insulin sensitivity (animal models)
- Reduced liver fat
- Wider safety margin than DNP (preclinical)
CagriSema reported benefits
- Enhanced weight loss vs monotherapy
- Dual appetite suppression
- Convenient single injection
- Improved metabolic parameters
- Potential 20-25% weight loss
Related comparisons
Research and educational reference only. Not medical advice.